이바이오젠

Ebiogen has obtained manufacturing certification from the Ministry of Food and Drug Safety (MFDS) for its BAROS Drug Detection Kit DOA1, a urine-based single-drug test for cocaine (COC). 

This certification, issued under In Vitro Diagnostic Medical Device Manufacturing Certificate No. 26-4310, represents another meaningful milestone that officially recognizes the quality and reliability of Ebiogen’s manufacturing and product development capabilities.

This achievement is particularly significant as it marks Ebiogen’s second MFDS manufacturing certification, following the earlier approval of its methamphetamine detection kit. With this additional certification, Ebiogen continues to strengthen its technological competitiveness and expand its portfolio in the field of rapid drug testing solutions. 

The newly obtained certification for the cocaine single-drug test also increases anticipation for the upcoming launch of the BAROS DOA6 urine-based 6-panel drug detection kit. This progression from single-analyte products to multi-panel testing solutions demonstrates Ebiogen’s continued commitment to innovation and its ability to respond to evolving market needs. It is also expected to further reinforce the BAROS drug detection kit product line, enhancing confidence in the company’s long-term business sustainability and growth potential.

More than just a regulatory milestone, this certification reflects Ebiogen’s position as a company capable of continuously developing and supplying reliable in vitro diagnostic products. Moving forward, we will remain committed to delivering trusted diagnostic solutions backed by high quality, accuracy, and consistent innovation.

Ebiogen will continue to expand its product portfolio and strengthen its capabilities in the in vitro diagnostics industry, with the goal of becoming a more trusted and competitive global partner.
We will continue to meet your expectations with the highest quality.